Everest Organics Downgraded to Strong Sell Amid Mixed Valuation and Weak Financial Trends

Quality Assessment: Weak Long-Term Fundamentals

Everest Organics’ quality parameters remain under pressure, reflecting weak long-term fundamentals. The company has experienced a negative compound annual growth rate (CAGR) of -7.30% in operating profits over the past five years, signalling deteriorating operational efficiency. Additionally, the average return on equity (ROE) stands at a modest 2.02%, indicating limited profitability generated per unit of shareholders’ funds. This low ROE is a critical factor in the downgrade, as it highlights the company’s struggle to deliver value to its investors.

Moreover, Everest Organics’ ability to service debt is constrained, with a high Debt to EBITDA ratio of 2.52 times. This elevated leverage ratio raises concerns about financial risk, especially in a sector where steady cash flows are essential for sustaining growth and innovation. The operating profit to interest coverage ratio for the latest quarter is also low at 2.43 times, underscoring the company’s limited cushion to meet interest obligations comfortably.

Valuation: Upgrade from Very Attractive to Attractive

Contrasting the weak quality metrics, Everest Organics’ valuation grade has improved from very attractive to attractive. The company currently trades at a price-to-earnings (PE) ratio of 47.41, which, while high, is supported by a remarkably low price-to-earnings-growth (PEG) ratio of 0.09. This suggests that the stock price is not excessively stretched relative to its earnings growth potential. The enterprise value to EBITDA ratio stands at 15.79, and the enterprise value to capital employed is a modest 2.51, both indicating reasonable valuation levels compared to peers.

When benchmarked against competitors such as Bliss GVS Pharma and Kwality Pharma, which are classified as very expensive with PE ratios of 39.08 and 35.83 respectively, Everest Organics appears more attractively priced. This valuation improvement is a key reason for the partial upgrade in the company’s mojo score, despite other negative factors.

Financial Trend: Flat Recent Performance Amid Profit Volatility

The company’s recent financial performance remains flat, with Q4 FY25-26 results showing no significant growth. The profit after tax (PAT) for the latest six months stood at ₹2.99 crores, reflecting a decline of 26.17% year-on-year. Operating profit margins have also stagnated, and the debtor turnover ratio is low at 1.63 times, indicating potential inefficiencies in receivables management.

Despite these challenges, Everest Organics reported a remarkable 527.7% increase in profits over the past year, a figure that contrasts sharply with its stock price performance. This divergence is partly explained by the company’s underperformance in the equity markets, where it has generated a negative return of -21.72% over the last 12 months, significantly lagging behind the BSE500 index’s modest 0.84% gain.

Technicals: Mixed Signals with Recent Price Movement

From a technical perspective, Everest Organics’ stock price has shown some short-term resilience. The share closed at ₹271.45 on 19 June 2026, up 3.79% from the previous close of ₹261.55. The stock’s 52-week trading range is wide, with a low of ₹197.00 and a high of ₹536.40, reflecting significant volatility. Over the past month, the stock has delivered a strong return of 12.36%, outperforming the Sensex’s 2.78% gain in the same period.

However, the longer-term technical outlook remains cautious. The stock’s year-to-date return is deeply negative at -46.33%, and its one-year return of -21.72% underscores persistent downward pressure. This mixed technical picture contributes to the overall Strong Sell rating, as short-term momentum is insufficient to offset fundamental weaknesses.

Comparative Industry Context

Within the Pharmaceuticals & Biotechnology sector, Everest Organics is classified as a micro-cap with a Mojo Score of 28.0 and a current Mojo Grade of Strong Sell, downgraded from Sell. Its valuation compares favourably to many peers, but its financial and operational metrics lag behind industry standards. For instance, competitors such as Venus Remedies and Fredun Pharma, despite being more expensive, demonstrate stronger operational metrics and more consistent profitability.

The company’s return on capital employed (ROCE) of 10.68% is modest but contributes to the attractive valuation grade. Still, this is insufficient to counterbalance the weak debt servicing capacity and flat profit trends, which weigh heavily on investor sentiment.

Summary and Outlook

Everest Organics Ltd’s downgrade to a Strong Sell rating by MarketsMOJO reflects a complex interplay of factors. While valuation metrics have improved, signalling a more attractive entry point relative to peers, the company’s weak long-term financial trends, poor debt servicing ability, and underwhelming profitability metrics overshadow these positives. The stock’s recent price gains and short-term momentum provide limited comfort against a backdrop of flat quarterly results and significant underperformance relative to the broader market.

Investors should approach Everest Organics with caution, recognising that the company’s micro-cap status and financial vulnerabilities pose considerable risks. The downgrade underscores the importance of a holistic analysis that balances valuation appeal with fundamental and technical realities in the Pharmaceuticals & Biotechnology sector.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today